The insulin sparing action of E4 can reduce high levels of circulating endogenous insulin and improve the glycemic control by activating the distal insulin signaling pathway independent of obesity, thereby improving NAFLD. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.